Drugs manufacturer Theramex has said the FemSeven Range of HRT patches will return to pharmacies this year after two years off the shelves.
The company said that after it acquired the UK marketing authorisation for FemSeven 50,75 and 100 (estradiol), FemSeven Conti (estradiol/levonorgestrel) and FemSeven Sequi (estradiol levonorgestrel), a number of quality issues emerged surrounding the products.
Theramex said it has “been working diligently to fix these issues” and that the entire range of FemSeven products “will be returning in 2021,” beginning with FemSeven Conti which is now available from Alliance Healthcare.
“We anticipate that the rest of the FemSeven portfolio will be available by mid-2021 and we will continue keep health care professionals informed of any changes,” the company said. “We would like to thank both patients and prescribers for their continued patience.”
The company will provide further updates via its website.